Unfortunately, the production of NRF2 direct inhibitors is a complex and unresolved issue in the oncologic field, thus, understanding the KEAP1-NRF2 axis role and regulation in different cancer types can provide interesting alternative therapeutic approaches. The gene discussed is NFE2L2; the disease is cancer.